previously showed that the proportions of MAIT cells were significantly higher in responders with metastatic melanoma to anti‐PD1 therapy, highlighting the potential value of MAITs as biomarkers for patient responses to anti‐PD‐1 therapy. Here, PDCD1 is linked to metastatic melanoma.